InMed to Present at Virtual Conferences in March 2021
March 03 2021 - 6:00PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company
developing cannabinoid-based pharmaceutical drug candidates
targeting diseases with high unmet medical need and leading the
clinical development of cannabinol (“CBN”), today announced that
Eric A. Adams, President and CEO of InMed, will be presenting at
investor conferences in March 2021. The details of each conference
are included below.
H.C. Wainwright Global Life Sciences
Conference Date: March
9-10th Presentation Details: The company
presentation will be available on demand beginning March 9th at 7am
EST, and can be found at the below link. The presentation will be
archived for 90 days following the conclusion of the event.
Presentation Link:
https://journey.ct.events/view/d9d5aa94-1651-4380-9c75-b8bf018118e6
33rd
Annual ROTH ConferenceDate: March
15-17th Presentation Details: Company CEO Eric A.
Adams will participate in a Fireside Chat with ROTH analyst Scott
Henry, CFA. Fireside Chat Date/Time:
Monday, March 15th at 4:30pm ESTFireside Chat
Link: https://wsw.com/webcast/roth35/inm/1678644
For 1x1s meetings with Management, conference participants can
send a request to info@inmedpharma.com. Information on each event,
as well as links to presentations as they become available, will be
posted on InMed’s event page, which can be found at:
www.inmedpharma.com/about/events.
About InMed: InMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”), in
diseases with high unmet medical need. The Company is dedicated to
delivering new therapeutic alternatives to patients that may
benefit from cannabinoid-based pharmaceutical drugs. For more
information, visit www.inmedpharma.com.
Investor Contact: Edison
Group Joe Green/Laine Yonker T:
+1.646.653.7030/+1.646.653.7035E: jgreen@edisongroup.com
lyonker@edisongroup.com |
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: presenting at conferences in March 2021,
including the H.C. Wainwright Global Life Sciences Conference and
the 33rd Annual ROTH Conference; leading the way in the clinical
development of cannabinol (CBN); developing a pipeline of
cannabinoid-based pharmaceutical drug candidates in diseases with
high unmet medical need; and delivering new therapeutic
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024